LITHIUM CARBONATE tablet extended release

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

LITHIUM CARBONATE (UNII: 2BMD2GNA4V) (LITHIUM CATION - UNII:8H8Z5UER66)

Disponible depuis:

Avera McKennan Hospital

DCI (Dénomination commune internationale):

LITHIUM CARBONATE

Composition:

LITHIUM CARBONATE 450 mg

Type d'ordonnance:

PRESCRIPTION DRUG

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

LITHIUM CARBONATE- LITHIUM CARBONATE TABLET, EXTENDED RELEASE
AVERA MCKENNAN HOSPITAL
----------
LITHIUM CARBONATE EXTENDED RELEASE TABLETS USP, 450 MG
RX ONLY
WARNING
Lithium toxicity is closely related to serum lithium levels, and can
occur at doses close to
therapeutic levels. Facilities for prompt and accurate serum lithium
determinations should be
available before initiating therapy (see DOSAGE AND ADMINISTRATION).
DESCRIPTION
Lithium Carbonate Extended Release Tablets USP contain lithium
carbonate, a white, light alkaline
powder with molecular formula Li
CO and molecular weight 73.89. Lithium is an element of the
alkali-metal group with atomic number 3, atomic weight 6.94 and an
emission line at 671 nm on the flame
photometer.
LITHIUM CARBONATE EXTENDED RELEASE TABLETS USP
Each round, speckled off-white to yellow, biconvex tablet debossed
with "54 346" on one side and
scored on the other side, contains lithium carbonate, 450 mg. Inactive
ingredients consist of ferric
oxide, magnesium stearate, povidone, sodium alginate, and sodium
starch glycolate.
Lithium Carbonate Extended Release Tablets USP, 450 mg are designed to
release a portion of the
dose initially and the remainder gradually; the release pattern of the
controlled release tablets reduces
the variability in lithium blood levels seen with the immediate
release dosage forms.
ACTIONS
Preclinical studies have shown that lithium alters sodium transport in
nerve and muscle cells and effects
a shift toward intraneuronal metabolism of catecholamines, but the
specific biochemical mechanism of
lithium action in mania is unknown.
INDICATIONS
Lithium Carbonate Extended Release Tablets USP are indicated in the
treatment of manic episodes of
manic-depressive illness. Maintenance therapy prevents or diminishes
the intensity of subsequent
episodes in those manic-depressive patients with a history of mania.
Typical symptoms of mania include pressure of speech, motor
hyperactivity, reduced need for sleep,
flight of ideas, grandiosity, elation, poor judgment, aggressi